



# Comparing the protective effects of local and remote ischemic preconditioning against ischemia-reperfusion injury in hepatectomy: a systematic review and network meta-analysis

Yaru Chen<sup>#</sup>, Jin Yan<sup>#</sup>, Kai Wang, Zhenghua Zhu

Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, The Fourth Military Medical University, Xi'an, China

*Contributions:* (I) Conception and design: Z Zhu, Y Chen; (II) Administrative support: None; (III) Provision of study materials or patients: Y Chen, J Yan, K Wang; (IV) Collection and assembly of data: Y Chen, J Yan, K Wang; (V) Data analysis and interpretation: Z Zhu, Y Chen; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

<sup>#</sup>These authors contributed equally to this work as co-first authors.

*Correspondence to:* Zhenghua Zhu, MD, PhD. Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, The Fourth Military Medical University, 127 Changle West Road, Xi'an 710032, China. Email: 2829204077@qq.com.

**Background:** Local ischemic preconditioning (LIPC) has been proven to be a protective strategy against hepatic ischemia-reperfusion injury (HIRI) during hepatectomy. Growing evidence suggests remote ischemic preconditioning (RIPC) has the potential to reduce liver injury in hepatectomy. Few studies have directly compared the protective effects of these two mechanical preconditioning strategies. Therefore, we performed a network meta-analysis to compare the efficacy of LIPC and RIPC for hepatic injury during liver resection.

**Methods:** We searched Cochrane, PubMed, Embase, and China National Knowledge Infrastructure (CNKI) from the database inception to January 2023. We included studies directly comparing the effectiveness of LIPC and RIPC and those comparing LIPC or RIPC with no-preconditioning in liver resection. Postoperative liver function and surgical events were analyzed. Data were expressed as standardized mean differences (SMDs) or odds ratios (ORs) and analyzed using network meta-analysis with random effects model.

**Results:** Following the screening of 268 citations, we identified 26 eligible randomized clinical trials (RCTs) involving 1,476 participants (LIPC arm: 789, RIPC arm: 859, no-preconditioning arm: 1,072). LIPC and RIPC were superior to no-preconditioning in reducing postoperative serum transaminase levels [aspartate aminotransferase (AST): SMD RIPC versus no-preconditioning:  $-2.05$ , 95% confidence interval (CI):  $-3.39$ ,  $-0.71$ ; SMD LIPC versus no-preconditioning:  $-1.10$ , 95% CI:  $-2.07$ ,  $-0.12$ ; alanine aminotransferase (ALT): SMD RIPC versus no-preconditioning:  $-2.24$ , 95% CI:  $-4.15$ ,  $-0.32$ ; SMD LIPC versus no-preconditioning:  $-1.32$ , 95% CI:  $-2.63$ ,  $-0.01$ ]. No significant difference was observed between RIPC and LIPC in postoperative liver function and surgical outcomes (AST: SMD RIPC versus LIPC:  $-0.95$ , 95% CI:  $-2.52$ ,  $0.62$ ; ALT: SMD RIPC versus LIPC:  $-0.91$ , 95% CI:  $-3.11$ ,  $1.28$ ). In addition, the subgroup analysis revealed the potential benefits of RIPC in improving liver function, especially in patients who diagnosed with cirrhosis or underwent major resection.

**Conclusions:** RIPC and LIPC could serve as effective strategies in relieving HIRI during hepatectomy. No significant differences were observed between LIPC and RIPC, however, RIPC may be an easily applicable strategy to relieve liver injury in hepatectomy.

**Keywords:** Local ischemic preconditioning (LIPC); remote ischemic preconditioning (RIPC); hepatic ischemia-reperfusion injury (HIRI); liver resection

Received: 29 October 2023; Accepted: 10 February 2024; Published online: 27 March 2024.

doi: 10.21037/tgh-23-95

View this article at: <https://dx.doi.org/10.21037/tgh-23-95>

## Introduction

Hepatic resection has been used worldwide for treating both benign and malignant liver masses (1,2). However, intraoperative hepatic bleeding remains a significant challenge (3-5). The Pringle maneuver, involving intermittent inflow occlusion during hepatectomy could effectively reduce blood loss; whereas, it raises concern regarding hepatic ischemia-reperfusion injury (HIRI) during hepatectomy (6), especially when combined with low central venous pressure (7). The severity of HIRI is associated with higher rates of postoperative morbidity and mortality (8,9). Thus, finding effective strategies to mitigate HIRI in liver resection is recognized as a research priority.

Local ischemic preconditioning (LIPC) is a protective strategy that exposes the liver to a temporary period of ischemia before hepatectomy, enabling adaptation to subsequent long-term ischemic insults. Experimental and clinical evidence has revealed that LIPC can ameliorate hepatic injury (10-16). In addition, a recent network meta-analysis (17) demonstrated that LIPC resulted in multiple beneficial clinical endpoints during elective liver resection. Despite these promising results, LIPC has not gained widespread adoption in clinical practice.

This may be partly due to the fact that LIPC can induce direct liver ischemia and necessitates additional surgical procedures, thereby increasing the surgical complexity and extending the operative time. Subsequently, remote ischemic preconditioning (RIPC), another mechanical preconditioning strategy, has been recognized for its effectiveness, as numerous studies have demonstrated its benefits within the same organ and in distant organs (18-21). RIPC involves one or more brief cycles achieved by inflating and deflating a standard blood pressure cuff placed on a limb before surgery to play a protective role in organ function. It offers several advantages such as user-friendly control, no need for additional surgical procedures, and no increase in surgical duration. These conveniences have facilitated its translation into clinical settings (22).

However, to our knowledge, no large randomized clinical trials (RCTs) have directly compared the effects of LIPC and RIPC on hepatic function in hepatectomy. Therefore, we performed a network meta-analysis to compare the efficacy of LIPC and RIPC for hepatic injury during liver resection. We present this article in accordance with the PRISMA-NMA reporting checklist (available at <https://tgh.amegroups.com/article/view/10.21037/tgh-23-95/rc>).

## Methods

This meta-analysis was prospectively registered on INPLASY (CRD202370007).

### Search strategy

The following databases were searched: Embase, PubMed, Cochrane Library, and China National Knowledge Infrastructure (CNKI) from database inception until January 2023. In addition, meta-analysis and references cited in the included studies were examined. A detailed search strategy is provided in [Appendix 1](#).

### Study selection

First, duplicates were removed by Endnote X9. Subsequently, three reviewers (Y.C., J.Y., and K.W.) screened the titles and abstracts of trials independently to select the eligible inclusions based on the inclusion and exclusion criteria. Full-text articles and their relevant references were carefully selected for further assessment. Disagreements were resolved by an independent reviewer (Z.Z.).

### Highlight box

#### Key findings

- Remote ischemic preconditioning (RIPC) and local ischemic preconditioning (LIPC) could serve as effective strategies in relieving hepatic ischemia-reperfusion injury (HIRI) during hepatectomy. No significant differences were observed between LIPC and RIPC, however, RIPC may become an easily applicable protective strategy to relieve liver injury in hepatectomy.

#### What is known and what is new?

- HIRI is a major hurdle to the success of hepatectomy. LIPC is known to be a protective strategy but limited in clinical practice due to its poor feasibility and invasiveness in hepatectomy. Growing evidence suggests that RIPC has protective effects against HIRI. Few studies have directly compared the protective effects of the two mechanical preconditioning methods.
- This study provided new evidence that RIPC has protective effects against HIRI as LIPC does.

#### What is the implication, and what should change now?

- The severity of HIRI is associated with higher rates of postoperative morbidity and mortality.
- More clinical investigations are needed to find more effective strategies to mitigate HIRI in liver resection, especially combined measures.

### *Data extraction*

Three authors (Y.C., J.Y., and K.W.) extracted data independently from the eligible studies, including study characteristics, participants' information, preconditioning types, and other interesting outcomes such as liver function and operative outcomes. Disagreements were settled by an independent reviewer (Z.Z.). All data were recorded in Microsoft Excel [2016].

### *Quality assessment*

The methodological quality of included trials and risk of bias were evaluated by the Cochrane Collaboration's tool which includes seven domains: allocation concealment, random sequence generation, incomplete outcome data, selective outcome reporting, blinding of participants and personnel, blinding of outcome assessment, and other biases. The risk of bias was graded as high, unclear, or low. The risk of bias in each trial was evaluated independently by three authors (Y.C., J.Y., and K.W.), and disagreements were discussed with an independent reviewer (Z.Z.) to reach an agreement.

### *Selection criteria*

Studies were selected based on specific inclusion criteria: (I) participants—humans with relevant diseases necessitating hepatectomy, aged over 18 years; (II) interventions—the intervention and comparator should include one of the following: LIPC versus RIPC, LIPC versus no-preconditioning, or RIPC versus no-preconditioning; (III) outcomes—reporting of outcome indicators reflecting liver function, such as aspartate aminotransferase (AST) or alanine aminotransferase (ALT), is required; and (IV) methodological criterion—prospective RCTs.

### *Exclusion criteria*

The following exclusion criteria were used: (I) liver transplantation studies; and (II) cluster or crossover randomized trials.

### *Statistical analysis*

We tried to contact study authors in cases where missing or unclear data were identified. When standard deviations (SDs) were unreported, they were computed from standard errors, P values, t values, confidence intervals (CIs), or

graphical representations. Random effects models were used for the network meta-analyses. Summary odds ratios (ORs) for dichotomous outcomes and standardized mean differences (SMD) for continuous outcomes, along with their corresponding 95% CIs, were derived through network meta-analysis. The network meta-analysis was executed using the network meta package within Stata (version 16.1). Prior to conducting the network meta-analysis, an assessment of the transitivity assumption was conducted by scrutinizing the characteristics of the included studies. Statistical heterogeneity was probed via pairwise meta-analyses. Discrepancies between direct and indirect sources of evidence were assessed employing both global and local methodologies. Global inconsistency was evaluated through a design-by-treatment test, while local inconsistency was gauged using a side-splitting approach. Secondary metrics of treatment effect, such as surface under the cumulative rank curve (SUCRA) probabilities and treatment rankings, were also computed. Publication bias was explored by constructing funnel plots and detecting asymmetry. Subgroup analyses were performed between groups with cirrhotic and noncirrhotic livers, groups with major and minor hepatectomies, and groups with different times of vascular exclusion.

### *Outcomes*

Primary outcomes: postoperative serum transaminase level, including AST and ALT on postoperative day 1 (POD1).

Secondary outcomes: other indicators to reflect liver function, like total bilirubin (TBIL) and outcomes presenting surgical process, including operative time, blood loss, and hospital stay.


## **Results**

### *Study characteristics*

In total, 268 studies were initially identified through the search strategy. After removing duplicates, 160 unique titles and abstracts were screened. Subsequently, 110 articles in the full-text review were assessed. Finally, 26 articles met eligibility for extraction (*Table 1*). The reasons for exclusion are shown in *Figure 1*.

### *Characteristics of the included studies*

Among the trials included in this network meta-analysis, 13 studies were conducted in Asia, and 13 were conducted



**Figure 1** Study flow diagram. RCT, randomized clinical trial.

in Europe. These studies were published between 2002 and 2023. The mean age of the participants was 54 (12.7) years, and 484 (62.8%) of the patients were women. Of the 26 studies, six were limited to older adults (aged >60 years) and 10 (38%) enrolled patients undergoing major liver resection.

In ten trials (59%), LIPC was performed through 10 min of inflow occlusion followed by 10 min of reperfusion. In 6 (35%) studies in the LIPC group, the Pringle maneuver was preceded by 5 min of ischemia and 5 min of reperfusion. In 1 (6%) study, LIPC was done by inflow occlusion for 10 min followed by reperfusion for 15 min before continuous hepatic vascular exclusion.

Regarding RIPC, 7 trials (77%) were performed through three cycles of 5 min of inflow occlusion followed by 5 min of reperfusion. In one study, RIPC was conducted by three cycles of 10 min of inflow occlusion followed by 10 min of

reperfusion. In another trial, RIPC was performed using four cycles of 5 min of inflow occlusion followed by 5 min of reperfusion.

We found no clear evidence of violations of the transitivity assumption when comparing characteristics of studies across comparisons (*Table 1*).

### Meta-analysis

*Figure 2* illustrates the network diagram of the total number of patients in each treatment. *Figures 3,4* illustrate the network of eligible comparisons for primary and secondary outcomes. *Figure 5* illustrates the ranking of treatments based on the SUCRA plot for each outcome.

### Primary outcomes

AST: a total of 24 studies with 1,476 participants were

**Table 1** Study and patient characteristics of included studies for analysis

ID	Source	Country	Type of preconditioning	Sample sizes, n	M/F, n	Age (years)	Ischemic time (min)	Resected volume	Cirrhosis, n	Steatosis, n
1	Choukèr <i>et al.</i> (14)	Germany	LIPC (10+10)×1	14	7/7	58±12	32±6.3	Minor resection	–	–
			No-preconditioning	34	23/11	61±10.8	35±11	–	–	
2	Clavien <i>et al.</i> (23)	Switzerland	LIPC (10+10)×1	50	22/28	54±14	36±5.9	Major resection	–	13
			No-preconditioning	50	25/25	57±14	35±6.8	–	–	
3	Heizmann <i>et al.</i> (24)	Switzerland	LIPC (10+10)×1	31	19/12	55±13	33±12	Minor resection	–	10
			No-preconditioning	30	18/13	57±14	34±14	–	8	
4	Li <i>et al.</i> (25)	China	LIPC (5+5)×1	14	12/2	50±10.7	18.0±3.6	Minor resection	13	–
			No-preconditioning	15	12/3	50±10.3	17.4±2.3	–	12	
5	Azoulay <i>et al.</i> (26)	France	LIPC (10+10)×1	30	18/12	58±14.6	44.5±9.2	Major resection	1	4
			No-preconditioning	30	16/14	61±14	47.7±8.3	–	0	4
6	Winblad <i>et al.</i> (27)	Sweden	LIPC (10+10)×1	16	8/8	64±14	39.5±11	Major resection	–	1
			No-preconditioning	16	10/6	64±9.4	44±10	–	–	3
7	Hahn <i>et al.</i> (28)	Hungary	LIPC (10+10)×1	80	42/38	57±2.2	33±2.9	Major resection	30	1
			No-preconditioning	80	37/43	55±1.8	28.5±6.2	–	30	2
8	Scatton <i>et al.</i> (29)	France	LIPC (10+10)×1	43	–	62±13.6	45±19.6	Major resection	–	–
			No-preconditioning	41	–	58.2±13	52.4±27.7	–	–	
9	Arkadopoulos <i>et al.</i> (30)	Greece	LIPC (10+15)×1	41	–	–	42±10	Major resection	–	–
			No-preconditioning	43	–	–	42±11	–	–	
10	Nuzzo <i>et al.</i> (31)	Italy	LIPC (10+10)×1	21	12/9	50±14	–	Minor resection	–	–
			No-preconditioning	21	11/10	57±11	–	–	–	
11	Petrowsky <i>et al.</i> (32)	Switzerland	LIPC (10+10)×1	36	23/13	56.5±2.3	37.3±1.5	Major resection	–	15
			No-preconditioning	37	15/22	58.9±2.3	40.0±2.1	–	–	20
12	Ye <i>et al.</i> (33)	China	LIPC (5+5)×1	50	39/11	50±15.3	–	Minor resection	33	–
			No-preconditioning	50	37/13	53±11.4	–	–	34	–
13	Smyrniotis <i>et al.</i> (34)	Greece	LIPC (10+10)×1	27	20/7	63±13.75	41.4±4.3	Major resection	–	–
			No-preconditioning	27	18/9	62±14.75	42.5±6.3	–	–	
14	Hou <i>et al.</i> (35)	China	LIPC (5+5)×1	24	–	47±14	–	Minor resection	12	–
			No-preconditioning	24	–	48±16	–	–	12	–
15	Ji <i>et al.</i> (36)	China	LIPC (5+5)×1	18	15/3	51.6±8.7	17.8±2.3	–	15	–
			No-preconditioning	16	12/4	48.6±8.6	17.9±1.8	–	13	–
16	Liang <i>et al.</i> (37)	China	LIPC (5+5)×1	14	12/2	50±10.7	18.0±3.6	Minor resection	13	–
			No-preconditioning	15	12/3	49.5±10.3	17.4±2.3	–	12	–
17	Jiang <i>et al.</i> (38)	China	LIPC (5+5)×1	35	25/10	47±11.2	24.8±9.5	–	30	–
			No-preconditioning	25	17/8	49±10.5	22.2±8.5	–	21	–

**Table 1** (continued)

Table 1 (continued)

ID	Source	Country	Type of preconditioning	Sample sizes, n	M/F, n	Age (years)	Ischemic time (min)	Resected volume	Cirrhosis, n	Steatosis, n
18	Teo <i>et al.</i> (39)	China	RIPC (5+5)×4	24	20/4	64±11.2	37±18.7	Minor resection	11	–
			No-preconditioning	26	19/7	67±8.4	29±13.5		7	–
19	Kanoria <i>et al.</i> (40)	England	RIPC (10+10)×3	8	7/1	–	–	–	–	–
			No-preconditioning	8	6/2	–	–	–	–	
20	Liu <i>et al.</i> (41)	China	RIPC (5+5)×3	69	59/10	51.7±10.6	22±4.6	Minor resection	56	–
			No-preconditioning	67	59/8	52.1±10.9	22.3±5		51	–
21	Zou <i>et al.</i> (42)	China	RIPC (5+5)×3	20	7/13	47±11.03	49.6±5.14	Major resection	–	–
			No-preconditioning	20	9/11	52±8.22	47.5±3.72		–	–
22	Wu <i>et al.</i> (43)	China	RIPC (5+5)×3	10	–	52±8	17±4	–	–	–
			No-preconditioning	10	–	49±7	17±3	–	–	–
23	Li <i>et al.</i> (44)	China	RIPC (5+5)×3	30	17/13	39±8.5	–	–	–	–
			No-preconditioning	30	16/14	40±7.2	–	–	–	–
24	Cao <i>et al.</i> (45)	China	RIPC (5+5)×3	30	11/19	35±9.1	15.4±3.1	Major resection	–	–
			No-preconditioning	30	8/22	38±11	16.2±2.6		–	–
25	Kong <i>et al.</i> (46)	China	RIPC (5+5)×3	30	16/9	54±9.77	42.2±6.79	Minor resection	–	–
			LIPC (5+5)×3	30	15/13	54±10.68	39±28.84		–	–
			No-preconditioning	30	17/10	54±12.13	41±7.93		–	–
26	Rakić <i>et al.</i> (47)	Croatia	RIPC (5+5)×3	20	–	–	–	Minor resection	–	–
			LIPC (10+15)×1	20	–	–	–		–	
			No-preconditioning	20	–	–	–		–	–

Values are presented as mean ± SD, unless otherwise indicated. Preconditioning types and implementation approaches were recorded. “(5+5)×3” indicates 5 min of ischemia followed by 5 min of reperfusion by three circles. n, number of events; M, male; F, female; LIPC, local ischemic preconditioning; RIPC, remote ischemic preconditioning; SD, standard deviation.


included in the network meta-analysis. RIPC and LIPC were more effective in preserving liver function than no-preconditioning (SMD RIPC versus no-preconditioning:  $-2.05$ , 95% CI:  $-3.39$ ,  $-0.71$ ; SMD LIPC versus no-preconditioning:  $-1.10$ , 95% CI:  $-2.07$ ,  $-0.12$ ). However, the network meta-analysis of indirect comparisons of RIPC and LIPC suggested no significant differences between RIPC and LIPC (SMD RIPC versus LIPC:  $-0.95$ , 95% CI:  $-2.52$ ,  $0.62$ ). Furthermore, RIPC had the highest SUCRA value for AST reduction, followed by LIPC, and no-preconditioning.

ALT: in total, 23 studies with 1,466 participants were included in the network meta-analysis. Compared with no-preconditioning, RIPC (SMD RIPC versus no-

preconditioning:  $-2.24$ , 95% CI:  $-4.15$ ,  $-0.32$ ) and LIPC (SMD LIPC versus no-preconditioning:  $-1.32$ , 95% CI:  $-2.63$ ,  $-0.01$ ) resulted in a significant reduction in ALT on POD1. However, no significant difference was observed between RIPC and LIPC (SMD RIPC versus LIPC:  $-0.91$ , 95% CI:  $-3.11$ ,  $1.28$ ). Similarly, RIPC had the highest SUCRA value for ALT reduction on POD1, followed by LIPC, and no-preconditioning.

### Secondary outcomes

TBIL: a total of 17 studies with 924 participants were included in the network meta-analysis. Compared with no-preconditioning, RIPC or LIPC exhibited no protective effect on liver function (SMD RIPC versus no-



**Figure 2** Network diagram depicting the total number of patients analyzed in each treatment arm. (A) AST, ALT, and TBIL on POD1. (B) Operative time, blood loss, and hospital stays. Circles represent the intervention as a node in the network; lines represent direct comparisons using RCTs; thickness of lines represents the number of RCTs included in each comparison, also represented by the numbers. AST, aspartate aminotransferase; POD1, postoperative day 1; LIPC, local ischemic preconditioning; RIPC, remote ischemic preconditioning; ALT, alanine aminotransferase; TBIL, total bilirubin; RCT, randomized controlled trial.

preconditioning:  $-0.28$ , 95% CI:  $-0.73$ ,  $0.16$ ; SMD LIPC versus no-preconditioning:  $-0.21$ , 95% CI:  $-0.49$ ,  $0.07$ ). Furthermore, the comparison between RIPC and LIPC revealed no decline in TBIL (SMD RIPC versus LIPC:  $-0.07$ , 95% CI:  $-0.57$ ,  $0.42$ ).

Surgical time: 22 studies with 1,386 participants were included in the network meta-analysis. No significant difference was observed between the three pairwise comparisons (SMD RIPC versus LIPC:  $0.11$ , 95% CI:  $-0.19$ ,  $0.42$ ; SMD RIPC versus no-preconditioning:  $0.05$ , 95% CI:  $-0.21$ ,  $0.30$ ; SMD LIPC versus no-preconditioning:  $-0.06$ , 95% CI:  $-0.24$ ,  $0.11$ ). LIPC had the highest SUCRA value for reducing surgical time.

Blood loss: 18 studies with 1,259 participants were

included in the network meta-analysis. LIPC caused less blood loss compared with no-preconditioning (SMD LIPC versus no-preconditioning:  $-0.24$ , 95% CI:  $-0.44$ ,  $-0.03$ ). However, the Network meta-analysis of indirect comparisons of RIPC and LIPC also suggested no difference in bleeding (SMD RIPC versus LIPC:  $0.10$ , 95% CI:  $-0.39$ ,  $0.60$ ). LIPC had the highest SUCRA value, followed by RIPC, and no-preconditioning.


Hospital stays: This network meta-analysis analyzed 14 studies with 1,024 participants. No statistical difference was observed between LIPC and no-preconditioning or RIPC and no-preconditioning or LIPC and RIPC (SMD LIPC versus no-preconditioning:  $-0.18$ , 95% CI:  $-0.54$ ,  $0.19$ ; SMD RIPC versus no-preconditioning:  $-0.06$ , 95%

A		
RIPC	-0.28 (-0.73, 0.16)	-0.07 (-0.57, 0.42)
	-	-
-2.05 (-3.39, -0.71)	No-preconditioning	-0.21 (-0.49, 0.07)
-2.24 (-4.15, -0.32)		-
-0.95 (-2.52, 0.62)	-1.10 (-2.07, -0.12)	LIPC
-0.91 (-3.11, 1.28)	-2.05 (-3.39, -0.71)	


  

B		
RIPC	-0.06 (-0.58, 0.46)	0.12 (-0.49, 0.72)
	-	-
0.05 (-0.21, 0.30)	No-preconditioning	-0.18 (-0.54, 0.19)
-0.13 (-0.60, 0.34)		-
0.11 (-0.19, 0.42)	-0.06 (-0.24, 0.11)	LIPC
-0.10 (-0.39, 0.60)	-0.24 (-0.44, -0.03)	

**Figure 3** Network meta-analysis. (A) AST, ALT, and TBIL on POD1. (B) Operative time, blood loss, and hospital stays. Comparisons should be read from left to right. The levels of AST, ALT, TBIL, operative time, blood loss, and hospital stays are located at the intersection between the column-defining treatment and the row-defining treatment. Data are in SMD (95% CI), and data below 0 favor the column-defining treatment. Light blue represents AST levels, dark blue represents ALT levels, and orange represents TBIL levels. Light pink represents operative time; pink represents blood loss; light yellow represents hospital stays. LIPC, local ischemic preconditioning; RIPC, remote ischemic preconditioning; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TBIL, total bilirubin; POD1, postoperative day 1; SMD, standardized mean difference, CI, confidence interval.



**Figure 4** Forest plots for network meta-analysis. SMD, standardized mean difference; CI, confidence interval; AST, aspartate aminotransferase; LIPC, local ischemic preconditioning; RIPC, remote ischemic preconditioning; ALT, alanine aminotransferase; TBIL, total bilirubin.



**Figure 5** SUCRA plot. (A) AST, ALT, TBIL on POD1. (B) Operative time, blood loss, and hospital stays. LIPC, local ischemic preconditioning; RIPC, remote ischemic preconditioning; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TBIL, total bilirubin; SUCRA, surface under the cumulative rank curve; POD1, postoperative day 1.

CI: -0.58, 0.46; SMD RIPC versus LIPC: 0.12, 95% CI: -0.49, 0.72). However, our results showed that LIPC had the highest SUCRA value, followed by RIPC, and no-preconditioning.

No inconsistency was found in our study, and the evaluation of local inconsistency for each primary outcome was presented in [Appendix 2](#). Moreover, the ranking of treatments based on the SUCRA plot for each outcome was shown in [Figure 5](#). Subsequently, we conducted subgroup analyses to explore cirrhosis, resected liver volume, and inflow occlusion time ([Figure 6](#)). These results did not substantially differ from those of the primary analyses for most of the comparisons. RIPC demonstrated protective effects in terms of AST and ALT levels on POD1, especially in terms of patients who had cirrhosis or undergone major resection ([Figure 6](#)). The Cochrane Collaborative bias risk tool was used to assess the risk of bias of the included studies. [Figure 7](#) shows the bias assessment of each methodological component of the eligible studies.

## Discussion


To our knowledge, this is the first meta-analysis study to directly compare the efficiency of LIPC and RIPC in patients undergoing hepatectomy. We found that LIPC and RIPC were superior to no-preconditioning in alleviating liver injury. Moreover, no significant difference was observed between the effect of LIPC and RIPC. Furthermore, in subgroup analysis, RIPC demonstrated potential protective effects on liver function after major liver resection or when patients diagnosed with cirrhosis. These findings provided evidence that RIPC had the potential to reduce HIRI during liver resection as well as LIPC did.

LIPC has been confirmed to have beneficial effects in relieving HIRI in animals and humans over the past three decades (48-51). Our study also found that LIPC offers protection in liver function which is consistent with the findings of the latest meta-analysis (52). This protection could be further enhanced by manipulation of apoptotic pathways, activating related signaling pathways or inhibiting hepatocyte apoptosis (53). While laboratory and experimental evidence is favorable, a major limitation to clinical application of LIPC is the potential to damage to the portal vein and its small branches. Furthermore, prior studies have not reached a consensus on the standardization of ischemia and reperfusion durations for LIPC. Most studies have followed a standardized protocol of 10 min of


ischemia followed by 10 min of reperfusion; however, the protocol remains controversial. Therefore, it is necessary to discover better ways to mitigate liver damage.

RIPC, as another form of mechanical preconditioning, can be achieved noninvasively by simple inflating and deflating a standard blood pressure cuff placed on a limb, which facilitates RIPC translation into the clinical settings. Initially demonstrated in the canine heart (54), its protective effect on heart was later confirmed in humans. Subsequent studies have shown that RIPC protects muscle flaps, brain, kidneys, and heart from ischemic injury (55-62). In recent years, numerous animal experiments have shown the protective effects of RIPC on the liver (63,64). Several small clinical trials have presented evidence supporting the potential benefit of RIPC during hepatectomy (40,43), but two trials with small samples failed to demonstrate liver protection with RIPC (41,65). Thus, the role of RIPC in liver protection remains controversial. Interesting, our study provides new insight into the potential effectiveness of RIPC in liver resection. This may be linked to the ability of RIPC to promote the regeneration of marginal liver remnants, leading to improved survival after extended hepatectomy in a vascular endothelial growth factor (VEGF) dependent manner (66).

Our study demonstrated that no significance difference was observed between LIPC and RIPC. Currently, there are only two RCTs directly comparing RIPC and LIPC. Our result aligns with the latest clinical trial designed by Kong *et al.* (46), while it contradicts to the findings of the other study (47). We speculate that this may be related to several possible reasons. Firstly, anesthesia may be a confounding factor in the role of RIPC in liver surgery. Many studies supported that volatile but not propofol was a positive influencing factor in RIPC for myocardial protection (67-69). Similar results were confirmed in kidney protection during cardiac surgery (55,70). Unfortunately, due to a lack of sufficient data, subgroup analysis of anesthetic methods was not conducted in our study. Nevertheless, five eligible studies in our study indicated the beneficial impact of RIPC on liver function, all of which utilized propofol. Therefore, propofol may enhance the effects of RIPC. As Kong' trial, patients in RIPC group received invasive anesthesia by propofol which had lower AST and ALT levels, while the anesthesia mode in another RCT directly comparing RIPC and LIPC was not clear. Future research is needed to confirm the impact of anesthesia on RIPC in liver resection. Secondly, different ischemic preconditioning protocols may influence the effects of these two strategies, including



**Figure 6** Forest plots for subgroup analyses. (A) AST on POD1. (B) ALT on POD1.  $I^2$  is employed to assess the heterogeneity of study results.  $I^2$  ranges from 0% to 100%, where 0% indicates no observed heterogeneity, and 100% signifies the maximum degree of heterogeneity. SMD, standardized mean difference; CI, confidence interval; LIPC, local ischemic preconditioning; RIPC, remote ischemic preconditioning; AST, aspartate aminotransferase; POD1, postoperative day 1; ALT, alanine aminotransferase.



**Figure 7** Assessment of risk of bias in the RCTs. (A) Risk of bias graph. (B) Risk of bias summary. Green represents low risk of bias; yellow represents unclear risk of bias; red represents high risk of bias. RCT, randomized controlled trial.

variations in the site, duration, intensity (71). Further research is needed to confirm the relationship between these factors and the effectiveness of LIPC and RIPC. Moreover, whether participants have other complications, the severity of diseases, and other factors can be crucial. Thus, individual differences may have an impact on the therapeutic efficacy.

There were some limitations that must be considered. First, laboratory indicators such as AST and ALT are commonly used as primary outcomes in clinical trials; however, they may not provide a comprehensive assessment of short-term recovery and clinical outcomes following liver surgery. Therefore, lacking sensitive and specific indicators reflecting liver function remains a significant concern in clinical studies, which needs to attract enough attention in future investigations. Additionally, given differences between eligible studies, clinical and statistical

heterogeneity may exist. While SUCRA plots were utilized to determine the ranking of relative outcomes, caution is warranted in interpreting their values, as the comparisons of SMD were not significant for most outcomes. Finally, due to insufficient data, the role of anesthetic methods as a confounding factor in the efficacy of RIPC and LIPC was not analyzed in our study.

**Conclusions**

RIPC and LIPC could serve as effective strategies in relieving HIRI during hepatectomy. No significant differences were observed between LIPC and RIPC, however, RIPC may become an easily applicable protective strategy to relieve liver injury in hepatectomy. More large-scale clinical trials are needed in the future to confirm the application of LIPC and RIPC in hepatectomy.

## Acknowledgments

Thanks to Dr. Lijun Shang and Dr. Bairen Wang for the language revision and other suggestions on the manuscript.

*Funding:* None.

## Footnote

*Reporting Checklist:* The authors have completed the PRISMA-NMA reporting checklist. Available at <https://tgh.amegroups.com/article/view/10.21037/tgh-23-95/rc>

*Peer Review File:* Available at <https://tgh.amegroups.com/article/view/10.21037/tgh-23-95/prf>

*Conflicts of Interest:* All authors have completed the ICMJE uniform disclosure form (available at <https://tgh.amegroups.com/article/view/10.21037/tgh-23-95/coif>). The authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. Heriot AG, Karanjia ND. A review of techniques for liver resection. *Ann R Coll Surg Engl* 2002;84:371-80.
2. Maki H, Hasegawa K. Advances in the surgical treatment of liver cancer. *Biosci Trends* 2022;16:178-88.
3. Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. *Ann Surg* 2002;236:397-406; discussion 406-7.
4. Dionigi G, Boni L, Rovera F, et al. Effect of perioperative blood transfusion on clinical outcomes in hepatic surgery for cancer. *World J Gastroenterol* 2009;15:3976-83.
5. Kooby DA, Stockman J, Ben-Porat L, et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. *Ann Surg* 2003;237:860-9; discussion 869-70.
6. Bahde R, Spiegel HU. Hepatic ischaemia-reperfusion injury from bench to bedside. *Br J Surg* 2010;97:1461-75.
7. Jones RM, Moulton CE, Hardy KJ. Central venous pressure and its effect on blood loss during liver resection. *Br J Surg* 1998;85:1058-60.
8. Cannistrà M, Ruggiero M, Zullo A, et al. Hepatic ischemia reperfusion injury: A systematic review of literature and the role of current drugs and biomarkers. *Int J Surg* 2016;33 Suppl 1:S57-70.
9. Franken C, Lau B, Putschakayala K, et al. Comparison of short-term outcomes in laparoscopic vs open hepatectomy. *JAMA Surg* 2014;149:941-6.
10. Banga NR, Homer-Vanniasinkam S, Graham A, et al. Ischaemic preconditioning in transplantation and major resection of the liver. *Br J Surg* 2005;92:528-38.
11. Desai KK, Dikdan GS, Shareef A, et al. Ischemic preconditioning of the liver: a few perspectives from the bench to bedside translation. *Liver Transpl* 2008;14:1569-77.
12. Gurusamy KS, Kumar Y, Pamecha V, et al. Ischaemic pre-conditioning for elective liver resections performed under vascular occlusion. *Cochrane Database Syst Rev* 2009;(1):CD007629.
13. O'Neill S, Leuschner S, McNally SJ, et al. Meta-analysis of ischaemic preconditioning for liver resections. *Br J Surg* 2013;100:1689-700.
14. Choukèr A, Martignoni A, Schauer R, et al. Beneficial effects of ischemic preconditioning in patients undergoing hepatectomy: the role of neutrophils. *Arch Surg* 2005;140:129-36.
15. Prieto I, Monsalve M. ROS homeostasis, a key determinant in liver ischemic-preconditioning. *Redox Biol* 2017;12:1020-5.
16. Schulz R, Walz MK, Behrends M, et al. Minimal protection of the liver by ischemic preconditioning in pigs. *Am J Physiol Heart Circ Physiol* 2001;280:H198-207.
17. Simillis C, Robertson FP, Afxentiou T, et al. A network meta-analysis comparing perioperative outcomes of interventions aiming to decrease ischemia reperfusion injury during elective liver resection. *Surgery* 2016;159:1157-69.
18. Moskowitz MA, Waeber C. Remote ischemic preconditioning: making the brain more tolerant, safely and inexpensively. *Circulation* 2011;123:709-11.
19. Pan JS, Sheikh-Hamad D. Remote ischemic

- preconditioning for kidney protection. *JAMA* 2015;313:2124-5.
20. Kleinbongard P, Skyschally A, Heusch G. Cardioprotection by remote ischemic conditioning and its signal transduction. *Pflugers Arch* 2017;469:159-81.
  21. Heusch G, Bøtker HE, Przyklenk K, et al. Remote ischemic conditioning. *J Am Coll Cardiol* 2015;65:177-95.
  22. Kloner RA. Clinical application of remote ischemic preconditioning. *Circulation* 2009;119:776-8.
  23. Clavien PA, Selzner M, Rüdiger HA, et al. A prospective randomized study in 100 consecutive patients undergoing major liver resection with versus without ischemic preconditioning. *Ann Surg* 2003;238:843-50; discussion 851-2.
  24. Heizmann O, Meimarakis G, Volk A, et al. Ischemic preconditioning-induced hyperperfusion correlates with hepatoprotection after liver resection. *World J Gastroenterol* 2010;16:1871-8.
  25. Li SQ, Liang LJ, Huang JF, et al. Ischemic preconditioning protects liver from hepatectomy under hepatic inflow occlusion for hepatocellular carcinoma patients with cirrhosis. *World J Gastroenterol* 2004;10:2580-4.
  26. Azoulay D, Lucidi V, Andreani P, et al. Ischemic preconditioning for major liver resection under vascular exclusion of the liver preserving the caval flow: a randomized prospective study. *J Am Coll Surg* 2006;202:203-11.
  27. Winbladh A, Björnsson B, Trulsson L, et al. Ischemic preconditioning prior to intermittent Pringle maneuver in liver resections. *J Hepatobiliary Pancreat Sci* 2012;19:159-70.
  28. Hahn O, Blázovics A, Váli L, et al. The effect of ischemic preconditioning on redox status during liver resections--randomized controlled trial. *J Surg Oncol* 2011;104:647-53.
  29. Scatton O, Zalinski S, Jegou D, et al. Randomized clinical trial of ischaemic preconditioning in major liver resection with intermittent Pringle manoeuvre. *Br J Surg* 2011;98:1236-43.
  30. Arkadopoulos N, Kostopanagiotou G, Theodoraki K, et al. Ischemic preconditioning confers antiapoptotic protection during major hepatectomies performed under combined inflow and outflow exclusion of the liver. A randomized clinical trial. *World J Surg* 2009;33:1909-15.
  31. Nuzzo G, Giuliante F, Vellone M, et al. Pedicle clamping with ischemic preconditioning in liver resection. *Liver Transpl* 2004;10:S53-7.
  32. Petrowsky H, McCormack L, Trujillo M, et al. A prospective, randomized, controlled trial comparing intermittent portal triad clamping versus ischemic preconditioning with continuous clamping for major liver resection. *Ann Surg* 2006;244:921-8; discussion 928-30.
  33. Ye B, Zhao H, Hou H, et al. Ischemic preconditioning provides no additive clinical value in liver resection of cirrhotic and non-cirrhotic patients under portal triad clamping: a prospective randomized controlled trial. *Clin Res Hepatol Gastroenterol* 2014;38:467-74.
  34. Smyrniotis V, Theodoraki K, Arkadopoulos N, et al. Ischemic preconditioning versus intermittent vascular occlusion in liver resections performed under selective vascular exclusion: a prospective randomized study. *Am J Surg* 2006;192:669-74.
  35. Hou H, Geng XP, Zhu LX, et al. The value of hepatic ischemic preconditioning in hepatectomy with a prospective randomized controlled study. *Zhonghua Wai Ke Za Zhi* 2009;47:586-9.
  36. Ji XQ, Li CL, Yang JC, et al. Application of ischemic preconditioning before hepatic vascular exclusion for resection of hepatocellular carcinoma. *Di Yi Jun Yi Da Xue Xue Bao* 2004;24:66-8, 71.
  37. Liang L, Li S, Huang J. The protective effect and mechanism of ischemic preconditioning for hepatic resection under hepatic blood inflow occlusion in hepatocellular carcinoma patients with cirrhosis. *Zhonghua Wai Ke Za Zhi* 2002;40:265-7.
  38. Jiang Y, Wu BQ, Qin XH, et al. Effect of ischemic preconditioning on hepatic cancer in perioperation. *Journal of Hepatopancreatobiliary Surgery* 2009;21:347-9.
  39. Teo JY, Ho AFW, Bulluck H, et al. Effect of remote ischemic preconditioning on liver injury in patients undergoing liver resection: the ERIC-LIVER trial. *HPB (Oxford)* 2020;22:1250-7.
  40. Kanoria S, Robertson FP, Mehta NN, et al. Effect of Remote Ischaemic Preconditioning on Liver Injury in Patients Undergoing Major Hepatectomy for Colorectal Liver Metastasis: A Pilot Randomised Controlled Feasibility Trial. *World J Surg* 2017;41:1322-30.
  41. Liu X, Cao L, Zhang T, et al. Effect of Remote Ischemic Preconditioning in Patients Undergoing Hepatectomy With Portal Triad Clamping: A Randomized Controlled Trial. *Anesth Analg* 2019;129:1742-8.
  42. Zou BY. Effect of dexmedetomidine combined with remote limb ischemic preconditioning on hepatic ischemia reperfusion injury in patients undergoing liver resection. Changsha: Hunan Normal University; 2021. doi: 10.27137/d.cnki.ghusu.2021.002020.
  43. Wu Y, Zhang Y, Hu XW, et al. Effect of remote ischemic

- preconditioning on post-operative liver function of patients undergoing hemihepatectomy. *Acta Universitatis Medicinalis Anhui* 2014;49:1472-4, 1475.
44. Li X, Long XJ, Hu YH, et al. Effect of limb remote ischemic preconditioning on levels of serum TNF- $\alpha$  and HMGB1 in liver operation. *Journal of Clinical Anesthesiology* 2015;31:1193-5.
  45. Cao YS. Effect of limb remote ischemic preconditioning on liver function in patients with hepatic hydatid disease after hepatectomy at high altitude. Xining: Qinghai University; 2021. doi: 10.27740/d.cnki.gqhdx.2021.000050.
  46. Kong E, Yuan C, Li Y, et al. Protective Efficiency Comparison of Direct and Remote Ischemic Preconditioning on Ischemia Reperfusion Injury of the Liver in Patients Undergoing Partial Hepatectomy. *Biomed Res Int* 2023;2023:2763320.
  47. Rakić M, Patrlj L, Amić F, et al. Comparison of hepatoprotective effect from ischemia-reperfusion injury of remote ischemic preconditioning of the liver vs local ischemic preconditioning of the liver during human liver resections. *Int J Surg* 2018;54:248-53.
  48. Rüdiger HA, Kang KJ, Sindram D, et al. Comparison of ischemic preconditioning and intermittent and continuous inflow occlusion in the murine liver. *Ann Surg* 2002;235:400-7.
  49. Peralta C, Fernández L, Panés J, et al. Preconditioning protects against systemic disorders associated with hepatic ischemia-reperfusion through blockade of tumor necrosis factor-induced P-selectin up-regulation in the rat. *Hepatology* 2001;33:100-13.
  50. Pasupathy S, Homer-Vanniasinkam S. Surgical implications of ischemic preconditioning. *Arch Surg* 2005;140:405-9; discussion 410.
  51. Compagnon P, Lindell S, Ametani MS, et al. Ischemic preconditioning and liver tolerance to warm or cold ischemia: experimental studies in large animals. *Transplantation* 2005;79:1393-400.
  52. de Oliveira GC, de Oliveira WK, Yoshida WB, et al. Impacts of ischemic preconditioning in liver resection: systematic review with meta-analysis. *Int J Surg* 2023;109:1720-7.
  53. Jiménez-Castro MB, Cornide-Petronio ME, Gracia-Sancho J, et al. Inflammation-Mediated Inflammation in Liver Ischemia-Reperfusion Injury. *Cells* 2019;8:1131.
  54. Przyklenk K, Bauer B, Ovize M, et al. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. *Circulation* 1993;87:893-9.
  55. Zarbock A, Schmidt C, Van Aken H, et al. Effect of remote ischemic preconditioning on kidney injury among high-risk patients undergoing cardiac surgery: a randomized clinical trial. *JAMA* 2015;313:2133-41.
  56. Endre ZH. Renal ischemic preconditioning: finally some good news for prevention of acute kidney injury. *Kidney Int* 2011;80:796-8.
  57. Hougaard KD, Hjort N, Zeidler D, et al. Remote ischemic preconditioning as an adjunct therapy to thrombolysis in patients with acute ischemic stroke: a randomized trial. *Stroke* 2014;45:159-67.
  58. Haapanen H, Herajärvi J, Arvola O, et al. Remote ischemic preconditioning protects the spinal cord against ischemic insult: An experimental study in a porcine model. *J Thorac Cardiovasc Surg* 2016;151:777-85.
  59. Addison PD, Neligan PC, Ashrafpour H, et al. Noninvasive remote ischemic preconditioning for global protection of skeletal muscle against infarction. *Am J Physiol Heart Circ Physiol* 2003;285:H1435-43.
  60. Thielmann M, Kottenberg E, Kleinbongard P, et al. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. *Lancet* 2013;382:597-604.
  61. Kleinbongard P, Peters J, Jakob H, et al. Persistent Survival Benefit From Remote Ischemic Pre-Conditioning in Patients Undergoing Coronary Artery Bypass Surgery. *J Am Coll Cardiol* 2018;71:252-4.
  62. Hausenloy DJ, Candilio L, Evans R, et al. Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery. *N Engl J Med* 2015;373:1408-17.
  63. Limani P, Linecker M, Oberkofler CE, et al. Remote Ischemic Preconditioning: A Novel Strategy in Rescuing Older Livers From Ischemia-reperfusion Injury in a Rodent Model. *Ann Surg* 2016;264:797-803.
  64. Oberkofler CE, Limani P, Jang JH, et al. Systemic protection through remote ischemic preconditioning is spread by platelet-dependent signaling in mice. *Hepatology* 2014;60:1409-17.
  65. Jung KW, Kang J, Kwon HM, et al. Effect of Remote Ischemic Preconditioning Conducted in Living Liver Donors on Postoperative Liver Function in Donors and Recipients Following Liver Transplantation: A Randomized Clinical Trial. *Ann Surg* 2020;271:646-53.
  66. Kambakamba P, Linecker M, Schneider M, et al. Novel Benefits of Remote Ischemic Preconditioning Through VEGF-dependent Protection From Resection-induced Liver Failure in the Mouse. *Ann Surg* 2018;268:885-93.

67. Zangrillo A, Musu M, Greco T, et al. Additive Effect on Survival of Anaesthetic Cardiac Protection and Remote Ischemic Preconditioning in Cardiac Surgery: A Bayesian Network Meta-Analysis of Randomized Trials. *PLoS One* 2015;10:e0134264.
68. Kottenberg E, Thielmann M, Bergmann L, et al. Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol - a clinical trial. *Acta Anaesthesiol Scand* 2012;56:30-8.
69. Pierce B, Bole I, Patel V, et al. Clinical Outcomes of Remote Ischemic Preconditioning Prior to Cardiac Surgery: A Meta-Analysis of Randomized Controlled Trials. *J Am Heart Assoc* 2017;6:e004666.
70. Zhou H, Yang L, Wang G, et al. Remote Ischemic Preconditioning Prevents Postoperative Acute Kidney Injury After Open Total Aortic Arch Replacement: A Double-Blind, Randomized, Sham-Controlled Trial. *Anesth Analg* 2019;129:287-93.
71. Peters J. Remote ischaemic preconditioning of the heart: remote questions, remote importance, or remote preconditions? *Basic Res Cardiol* 2011;106:507-9.

doi: 10.21037/tgh-23-95

**Cite this article as:** Chen Y, Yan J, Wang K, Zhu Z. Comparing the protective effects of local and remote ischemic preconditioning against ischemia-reperfusion injury in hepatectomy: a systematic review and network meta-analysis. *Transl Gastroenterol Hepatol* 2024;9:13.